Getein Biotech Inc603387
▲ PositiveCapitalrelevance
Net profit of 184 million yuan reported in interim results.
Impact on stocks 1
Others
Getein Biotech IncGetein Biotech's 2026 interim report shows net profit of 184 million yuan
Earnings
Getein Biotech released its 2026 interim report on August 27, 2026. During the reporting period, the company's total operating revenue was 555 million yuan, net profit attributable to the parent company was 184 million yuan, and net cash inflow from operating activities was 189 million yuan. The company's latest asset-liability ratio was 19.21%, and gross margin was 69.09%, down 1.25 percentage points from the previous quarter and down 0.27 percentage points from the same period last year. The latest return on equity was 6.27%. Diluted earnings per share were 0.36 yuan, total asset turnover was 0.15 times, and inventory turnover was 0.92 times. The company had 30,700 shareholders, and the top ten shareholders held 245 million shares, accounting for 48.39% of total share capital.
Getein Biotech IncNet profit of 184 million yuan reported in interim results.